4S2N
OXA-48 in complex with Avibactam at pH 8.5
4S2N の概要
| エントリーDOI | 10.2210/pdb4s2n/pdb |
| 分子名称 | Beta-lactamase, (2S,5R)-1-formyl-5-[(sulfooxy)amino]piperidine-2-carboxamide, ... (4 entities in total) |
| 機能のキーワード | hydrolase-antibiotic complex, hydrolase/antibiotic |
| 由来する生物種 | Klebsiella pneumoniae 詳細 |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 122741.93 |
| 構造登録者 | |
| 主引用文献 | King, D.T.,King, A.M.,Lal, S.M.,Wright, G.D.,Strynadka, N.C. Molecular Mechanism of Avibactam-Mediated beta-Lactamase Inhibition. ACS Infect Dis, 1:175-184, 2015 Cited by PubMed Abstract: Emerging β-lactamase-mediated resistance is threatening the clinical utility of the single most prominent class of antibacterial agents used in medicine, the β-lactams. The diazabicyclooctane avibactam is able to inhibit a wider range of serine β-lactamases than has been previously observed with β-lactamase inhibitors such as the widely prescribed clavulanic acid. However, despite its broad-spectrum activity, variable levels of inhibition have been observed for molecular class D β-lactamases. In order to better understand the molecular basis and spectrum of inhibition by avibactam, we provide structural and mechanistic analysis of the compound in complex with important class A and D serine β-lactamases. Herein, we reveal the 1.7- and 2.0-Å-resolution crystal structures of avibactam covalently bound to class D β-lactamases OXA-10 and OXA-48. Furthermore, a kinetic analysis of key active-site mutants for class A β-lactamase CTX-M-15 allows us to propose a validated mechanism for avibactam-mediated β-lactamase inhibition including a unique role for S130, which acts as a general base. This study provides molecular insights that will aid in the design and development of avibactam-based chemotherapeutic agents effective against emerging drug-resistant microorganisms. PubMed: 27622530DOI: 10.1021/acsinfecdis.5b00007 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






